<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Quick Guide: Top 3 AML Approval Trends for 2017

FDA Drug Approval image with Featured banner and pills in the background.

FDA Drug Approval image with Featured banner and pills in the background. Acute myeloid leukemia has been the focus of much drug development, but few drug approvals, for the past few decades. While there have been significant research efforts into characterizing AML, and improving patient outcomes, the standard therapy for most subtypes of newly diagnosed AML has remained unchanged for the last 40 years.

That is until 2017, when new targeted agents have finally reached the market. This post reviews this year’s pivotal approvals, and takes a look at what could be coming next.

First AML Treatment Targeting FLT-3 Mutated Disease

Back in April, Novartis received FDA approval for Rydapt® (midostaurin), currently the only approved targeted therapy for newly diagnosed FLT-3 mutated AML, which was approved in the EU recently.

FLT3 is a cell-surface receptor, which plays a role in a variety of blood cancers. FLT3 mutations are seen in around 1/3 of US AML patients, and can result in faster disease progression, higher relapse rates, and lower rates of survival than other forms of AML.

Rydapt is a multi-targeted protein kinase inhibitor that is active against FLT3, which provides an exciting new targeted treatment option for this AML subgroup (specifically for patients who are shown to be FLT3 mutation positive by an approved companion diagnostic). The clinical trial data on which the approval is based shows that newly diagnosed FLT3+ patients who received Rydapt + chemotherapy had significant improvement in OS, with a 23% reduction in the risk of death compared with chemotherapy alone.

Gemtuzumab Ozogamicin Back on the Market

Another approval for newly diagnosed patients saw a withdrawn drug return to market. Mylotarg® from Pfizer is an antibody-drug conjugate targeting CD33, an antigen expressed on the surface of myeloblasts in up to 90% of AML patients.

Originally on the market from 2000 to 2010, Mylotarg was then available at a higher dose in patients with CD33-positive AML who had experienced their first relapse and were 60 years or older, and who were not suitable candidates for other cytotoxic chemotherapy. The drug was pulled in the US in 2010 due to toxicity issues and a failure to confirm clinical benefit.

Now, the drug is available at a lower dose for adults with newly diagnosed CD33+ AML, and adults and children 2 years and older with relapsed or refractory CD33-positive AML – the first therapy with an indication specifically including pediatric AML. The 2017 approval is supported by a raft of new clinical data, with Mylotarg and chemotherapy combinations showing increased OS compared with best supportive care.

First IDH2 Mutation Inhibitor Approved

Another subgroup of AML patients with a specific mutation also gained an extra treatment option this year. IDH2 mutations are found in around 12% of all AML patients, and block normal blood cell development, resulting in an overabundance of immature blood cells.

The new approval of the first-in-class targeted IDH2 inhibitor (Idhifa®, Celegene/Agois) is for relapsed or refractory AML patients, with IDH2 mutation detected by companion diagnostic. As AML is particularly difficult to treat in the relapsed or refractory setting, this new agent provides a much needed new therapeutic option.

What Next? Potential New Targets Include IDH1, BCL-2, and Resistance to Overcome

With these targeted agents approved, there is now a raft of agents targeting the same mutations, or other novel mutations, undergoing clinical development. Kadia et al, provided a thorough review of upcoming AML drugs before these latest approvals, with a few interesting agents reviewed here.

IDH1 Inhibitors could follow IDH2

Agios has a full IDH program underway, and following Idhifa approval, the next agent in clinical trials is ivosidenib, a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein. A number of clinical trials are ongoing in AML across adult and pediatric indications for newly diagnosed and relapsed disease, with Agios hoping to replicate their IDH2 success with this related subgroup.

BCL-2 and IDH2 Mutations could be Synthetically Lethal

Another approach to AML treatment involves activating the intrinsic or mitochondrial pathway of apoptosis, which is regulated by the BCL-2 protein family. This has led to research targeting this protein family, which has resulted in the development of ventoclax, a ‘BH3-mimetic’ and BCL-2 small molecule inhibitor, which has breakthrough therapy designation in AML.

In a clinical trial testing this agent, antileukemic activity was observed particularly in patients with IDH mutations, which suggest that BCL-2 could be a synthetic lethal partner for IDH2 mutated AML, which could lead to AML mutations being a biomarker for response and a guide to clinical combination therapies.

Resistance to FLT3 Inhibitors to be Overcome

Even though the first FLT3 inhibitor has only just been approved, we already need to think about resistance. It is well known that treatment resistance rapidly occurs, with acquired resistance mutations already identified. Newer inhibitors are in development with activity against FLT3-ITD as well as point mutations such as FLT3-D835 (e.g. crenolanib). A number of clinical trials are ongoing for this agent, including in AML.

Immunotherapy Research also Ongoing

Immunotherapy approvals are coming thick and fast in oncology, and include gemtuzumab ozogamicin for AML as detailed above. Other antibody approaches which have proved successful in ALL are lagging behind in AML, where it is more difficult to choose an appropriate target antigen from the more ubiquitous expression pattern overlapping with healthy hematopoiesis.

Lichtenegger et al, cover the recent developments and current status of the 5 most promising immunotherapy concepts in AML:

  1. antibody-drug conjugates such as gemtuzumab ozogamicin
  2. T cell-recruiting antibody constructs
  3. CAR T therapy
  4. checkpoint inhibitors
  5. dendritic cell vaccination

and review which agents are likely to join the targeted agents above battling to be the next new drug approved in AML.


Related Posts